RxDoctor Payments Data

Seth Hahs, MD

Internal Medicine · Salem, ILNPI 1154542132

Payments from drug & device makers

$486in general payments, 2019–2025

Across 27 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$124
  • Sunovion Pharmaceuticals Inc.$91
  • Pfizer$69
  • Astellas Pharma US Inc$33
  • Novo Nordisk$33
  • Teva Pharmaceuticals USA, Inc.$24
  • plus $111 from 6 others

What the payments were for

  • Food & beverage$486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$486 in reported general payments places this provider in the 65th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$38,358
Medicare patients
151
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$148,967
OzempicSemaglutide69$81,327
JanuviaSitagliptin Phosphate87$77,650
JardianceEmpagliflozin81$55,804
TrulicityDulaglutide39$49,185
XareltoRivaroxaban49$47,557
ArexvyRsvpref3 Antigen/As01e/Pf152$46,959
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$31,378
EntrestoSacubitril/Valsartan34$28,897
FarxigaDapagliflozin Propanediol23$21,374
ShingrixVaricella-Zoster Ge/As01b/Pf93$20,118
SymbicortBudesonide/Formoterol Fumarate63$18,809
Tresiba Flextouch U-100Insulin Degludec35$17,642
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$17,439
Breo ElliptaFluticasone/Vilanterol38$15,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$148,967253 claims
GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta, Incruse Ellipta$21$119,602329 claims
Novo NordiskOzempic$33$81,32769 claims
Johnson & JohnsonXarelto, Invokana$21$54,61862 claims
NovartisEntresto$124$28,89734 claims
Astellas Pharma US IncMyrbetriq$33$9,42711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Salem

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →